Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    nicotinamide mononucleotide, nmn

Evaluate the Efficacy and Safety of Uthever NMN(Nicotinamide Mononucleotide, a Form of Vitamin B3) (NMN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04228640
Recruitment Status : Not yet recruiting
First Posted : January 14, 2020
Last Update Posted : March 11, 2020
Sponsor:
Information provided by (Responsible Party):
EffePharm LTD

Brief Summary:
This will be a multi-center, two arm study in 66 healthy adults. Subjects will complete a screening visit (V1, Day -7) to determine eligibility for the study based on Inclusion & Exclusion Criteria, patient history and safety measures. Eligibility confirmation will be done on visit 2 (Day 1). Patients successfully completing screen will be assigned to either of the two treatments. Subjects will receive the treatment for at-home use and will also be given diaries for recording information of medication, and adverse events. At 2 different intervals i.e. Day 30 and Day 60 (V3, V4) subjects will return to the clinic to review and collect patient diaries, safety data and medication reconciliation. Efficacy and safety assessments will be done at baseline, Day 30 and Day 60 .

Condition or disease Intervention/treatment Phase
Aging Other: NMN Other: Placebo Not Applicable

Detailed Description:

Sixty-six healthy male or female middle-aged or older subjects will be assigned in 1:1 ratio to treatment with the test product, NMN or Placebo in this double-blind, randomized, placebo-controlled study. All 66 enrolled subjects will be instructed to take two capsules of either NMN or Placebo once a day after breakfast for 60 days daily. Subjects will be required to use diaries to document the date and time of study treatments including any missed doses and the occurrence of any adverse events.

The duration of each subject's participation in the study will be of 60 days.

Scheduled study visits will include:

  • Visit 1 (Screening, Day -4)
  • Visit 2 (Baseline/Randomization visit, Day 1)
  • Visit 3 (Day 30).
  • Visit 4 (End of study, Day 60) A window (± 2 days) will be considered acceptable for each scheduled visit following the baseline visit.

During Visit 1 (Screening), informed consent will be obtained before any study procedures take place. After subject has been consented, medical history will then be documented, including the concomitant medications (if any). Physical examination and ECG will be carried out for all subjects. Subjects' vital signs will be recorded along with pulse pressure (PP).Their laboratory investigations like Hematology, Clinical chemistry and Urinalysis will be done. They shall undergo the screening procedure by inclusion and exclusion criteria. Subject's demography data will be collected. They will be given instructions for the next visit.

At Visit 2 (Day 1, Baseline visit), eligibility confirmation will be done, and each enrolled subject will be randomly assigned in double-blind fashion, in 1:1 ratio to the test product or the Placebo. Blinded investigational product will be dispensed to subjects who meet all the inclusion and none of the exclusion criteria. Subjects will be instructed to take two capsules of the either placebo or NMN once a day with ambient temperature water after breakfast. They shall be recording the dosing details in subject diaries. The first dose of Investigational Product will be taken by the subject at home. Subjects will be evaluated through SF-36 questionnaire for their health. They will be required to answer few questions pertaining to their health. (PI, CRC or site staff will fill SF-36 questionnaire in visit 2, 3 and 4 by asking the subject). All the baseline assessments for efficacy will be performed.

At visit 3 (Day 30) and visit 4 (Day 60), subjects will return to the clinic to review and collect subjects' diaries, safety data, and medication reconciliation. Efficacy and safety assessments will be done at both the visits.

Subjects will be asked to bring their subject diaries and used/unused Investigational Products every time they visit the site. Enough quantity of Investigational Product will be dispensed every visit. Subjects' vital signs will be recorded along with pulse pressure (PP) at all visits. Adverse event assessment and concomitant assessment will be done at each visit along with compliance with drug applications.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A Multicenter, Randomized, Double-Blind, Placebo-Controlled
Masking: Double (Participant, Investigator)
Masking Description: Randomized, Double-Blind
Primary Purpose: Prevention
Official Title: A Multicentre, Randomized, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN), an Orally Administered Supplementation in Middle Aged and Older Adults.
Estimated Study Start Date : March 15, 2020
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : August 2020

Arm Intervention/treatment
Experimental: Investigational Product
Ingredient: NMN Dosage form: Capsule, 150 mg/capsule Frequency: 2 capsules per day Duration: 60 days
Other: NMN
Investigational Product

Placebo Comparator: Placebo
Ingredient: Starch powder Dosage form: Capsule, 150 mg/capsule Frequency: 2 capsules per day Duration: 60 days
Other: Placebo
Starch Powder




Primary Outcome Measures :
  1. Blood cellular NAD+ concentration in serum [ Time Frame: Day 2 ]
    Evaluation of Blood cellular NAD+ concentration in serum inter group comparison from baseline to the end of study

  2. Blood cellular NAD+ concentration in serum [ Time Frame: Day 30 ]
    Evaluation of Blood cellular NAD+ concentration in serum inter group comparison from baseline to the end of study

  3. Blood cellular NAD+ concentration in serum [ Time Frame: Day 60 ]
    Evaluation of Blood cellular NAD+ concentration in serum inter group comparison from baseline to the end of study

  4. Blood cellular NADH concentration in serum [ Time Frame: Day 2 ]
    Evaluation of Blood cellular NADH concentration in serum inter group comparison from baseline to the end of study

  5. Blood cellular NADH concentration in serum [ Time Frame: Day 30 ]
    Evaluation of Blood cellular NADH concentration in serum inter group comparison from baseline to the end of study

  6. Blood cellular NADH concentration in serum [ Time Frame: Day 60 ]
    Evaluation of Blood cellular NADH concentration in serum inter group comparison from baseline to the end of study

  7. Six minutes walking endurance test [ Time Frame: Day 2 ]
    Evaluation of Six minutes walking endurance test inter group comparison from baseline to the end of study

  8. Six minutes walking endurance test [ Time Frame: Day 30 ]
    Evaluation of Six minutes walking endurance test inter group comparison from baseline to the end of study

  9. Six minutes walking endurance test [ Time Frame: Day 60 ]
    Evaluation of Six minutes walking endurance test inter group comparison from baseline to the end of study

  10. Systolic [ Time Frame: Day 2 ]
    Evaluation of Systolic blood pressure inter group comparison from baseline to the end of study

  11. Systolic [ Time Frame: Day 30 ]
    Evaluation of Systolic blood pressure inter group comparison from baseline to the end of study

  12. Systolic [ Time Frame: Day 60 ]
    Evaluation of Systolic blood pressure inter group comparison from baseline to the end of study

  13. Diastolic blood pressure [ Time Frame: Day 2 ]
    Evaluation of diastolic blood pressure inter group comparison from baseline to the end of study

  14. Diastolic blood pressure [ Time Frame: Day 30 ]
    Evaluation of diastolic blood pressure inter group comparison from baseline to the end of study

  15. Diastolic blood pressure [ Time Frame: Day 60 ]
    Evaluation of diastolic blood pressure inter group comparison from baseline to the end of study

  16. Pulse pressure [ Time Frame: Day 2 ]
    Evaluation of Pulse Pressure inter group comparison from baseline to the end of study

  17. Pulse pressure [ Time Frame: Day 30 ]
    Evaluation of Pulse Pressure inter group comparison from baseline to the end of study

  18. Pulse pressure [ Time Frame: Day 60 ]
    Evaluation of Pulse Pressure inter group comparison from baseline to the end of study

  19. SF-36 questionnaire [ Time Frame: Day 2 ]
    Evaluation of SF-36 questionnaire inter group comparison from baseline to the end of study

  20. SF-36 questionnaire [ Time Frame: Day 30 ]
    Evaluation of SF-36 questionnaire inter group comparison from baseline to the end of study

  21. SF-36 questionnaire [ Time Frame: Day 60 ]
    Evaluation of SF-36 questionnaire inter group comparison from baseline to the end of study


Secondary Outcome Measures :
  1. Adverse events [ Time Frame: Day 2 ]
    Evaluation of Adverse events

  2. Adverse events [ Time Frame: Day 30 ]
    Evaluation of Adverse events

  3. Adverse events [ Time Frame: Day 60 ]
    Evaluation of Adverse events

  4. Laboratory parameter (blood chemistry) [ Time Frame: Day 1 ]
    Evaluation of Laboratory parameter (blood chemistry) changes from baseline to end of the study

  5. Laboratory parameter (blood chemistry) [ Time Frame: Day 30 ]
    Evaluation of Laboratory parameter (blood chemistry) changes from baseline to end of the study

  6. Laboratory parameter (blood chemistry) [ Time Frame: Day 60 ]
    Evaluation of Laboratory parameter (blood chemistry) changes from baseline to end of the study

  7. Laboratory parameter (lipid profile) [ Time Frame: Day 1 ]
    Evaluation of Laboratory parameter (lipid profile) changes from baseline to end of the study

  8. Laboratory parameter (lipid profile) [ Time Frame: Day 30 ]
    Evaluation of Laboratory parameter (blood chemistry, lipid profile, LFT and RFT) changes from baseline to end of the study

  9. Laboratory parameter (lipid profile) [ Time Frame: Day 60 ]
    Evaluation of Laboratory parameter (lipid profile) changes from baseline to end of the study

  10. Laboratory parameter (LFT ) [ Time Frame: Day 1 ]
    Evaluation of Laboratory parameter (LFT ) changes from baseline to end of the study

  11. Laboratory parameter (LFT) [ Time Frame: Day 30 ]
    Evaluation of Laboratory parameter (LFT ) changes from baseline to end of the study

  12. Laboratory parameter (LFT) [ Time Frame: Day 60 ]
    Evaluation of Laboratory parameter (LFT ) changes from baseline to end of the study

  13. Laboratory parameter (RFT) [ Time Frame: Day 1 ]
    Evaluation of Laboratory parameter (RFT) changes from baseline to end of the study

  14. Laboratory parameter (RFT) [ Time Frame: Day 30 ]
    Evaluation of Laboratory parameter (RFT) changes from baseline to end of the study

  15. Laboratory parameter (RFT) [ Time Frame: Day 60 ]
    Evaluation of Laboratory parameter (RFT) changes from baseline to end of the study

  16. Drop out due to adverse events [ Time Frame: Day 2 ]
    Number of participants that dropout due to adverse events including lab values

  17. Drop out due to adverse events [ Time Frame: Day 30 ]
    Number of participants that dropout due to adverse events including lab values

  18. Drop out due to adverse events [ Time Frame: Day 60 ]
    Number of participants that dropout due to adverse events including lab values


Other Outcome Measures:
  1. BMI [ Time Frame: Day 1 ]
    Monitoring of BMI inter group comparison from baseline to the end of study

  2. BMI [ Time Frame: Day 2 ]
    Monitoring of BMI inter group comparison from baseline to the end of study

  3. BMI [ Time Frame: Day 30 ]
    Monitoring of BMI inter group comparison from baseline to the end of study

  4. BMI [ Time Frame: Day 60 ]
    Monitoring of BMI inter group comparison from baseline to the end of study

  5. HOMA [ Time Frame: Day 2 ]
    Monitoring of HOMA inter group comparison from baseline to the end of study

  6. HOMA [ Time Frame: Day 60 ]
    Monitoring of HOMA inter group comparison from baseline to the end of study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male/females of 40 to 65 years of age
  2. Body Mass Index (BMI) between 18.5 and 35 kg/m2
  3. Able to provide written Informed Consent
  4. Able to follow verbal and written study directions
  5. Must not be taking or be willing to take any supplements containing any form of niacin for seven days prior to baseline and for the duration of the study.
  6. Able to maintain consistent diet and lifestyle habits throughout the study
  7. Male and female subjects must be willing to agree to use effective contraceptive methods while on treatment and for 3 months after the completion of study
  8. Willing to consume assigned dietary supplements for 2 months

Exclusion Criteria:

  1. Participants on current use of prescription or over-the-counter nicotinic acid
  2. Use of statin drugs
  3. Having used any tobacco product or used a recreational drug in the past 6 months
  4. Having abnormal screening laboratory test values or other lab test result(s) that would preclude study participation in the judgment of the investigator
  5. Documented presence of atherosclerotic disease and/or cardiopulmonary disease
  6. History of drug or alcohol abuse
  7. History of unstable depression or mental illness within the last 6 months for which the investigator believes could impact the participant's ability to comply with study requirements
  8. Unwilling to discontinue use of conventional multivitamin/mineral or other supplements at least two weeks prior to the study start
  9. Participating in or planning to begin a weight loss diet during the study period
  10. Chronic use of over-the-counter medication which would interfere with study endpoints
  11. Lifestyle or schedule incompatible with the study protocol
  12. Known hypersensitivity to the drug components used during the study
  13. Women with positive result for urinary beta human chorionic gonadotropin or gestation period or breastfeeding
  14. Other diseases or medications, according to the investigator, that would interfere directly in the results of the study or jeopardize the health of the participant.
  15. Currently, or within the past 30 days, enrolled in a different clinical investigation
  16. Inability to provide a venous blood sample
  17. Unable or unwilling to provide written informed consent for participation in study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04228640


Contacts
Layout table for location contacts
Contact: Hank Hwang +86(21)57709202 hank@effepharm.com
Contact: Alex Shen +86(21)57709202 alex@effepharm.com

Sponsors and Collaborators
EffePharm LTD
Investigators
Layout table for investigator information
Principal Investigator: Ganesh Avhad Swasthiye Clinic and Research Center
Layout table for additonal information
Responsible Party: EffePharm LTD
ClinicalTrials.gov Identifier: NCT04228640    
Other Study ID Numbers: EFFE-CT-01
First Posted: January 14, 2020    Key Record Dates
Last Update Posted: March 11, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by EffePharm LTD:
Anti- Aging
Workout Enhancer